Johnson & Johnson [NYSE: JNJ] stock went on an upward path that rose over 0.87% on Monday, amounting to a one-week price decrease of less than -0.57%. The company report on November 1, 2022 that Johnson & Johnson to Acquire Abiomed.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery.
Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need.
Over the last 12 months, JNJ stock rose by 5.84%. The one-year Johnson & Johnson stock forecast points to a potential upside of 5.86. The average equity rating for JNJ stock is currently 2.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $454.55 billion, with 2.63 billion shares outstanding and 2.61 billion shares in the current float. Compared to the average trading volume of 7.19M shares, JNJ stock reached a trading volume of 6619932 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Johnson & Johnson [JNJ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $183.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on October 18, 2022. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $185 to $178. The new note on the price target was released on October 14, 2022, representing the official price target for Johnson & Johnson stock.
The Average True Range (ATR) for Johnson & Johnson is set at 2.90, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 4.73. The Price to Book ratio for the last quarter was 6.09, with the Price to Cash per share for the same quarter was set at 12.97. Price to Free Cash Flow for JNJ in the course of the last twelve months was 73.08 with Quick ratio for the last quarter at 1.20.
JNJ Stock Performance Analysis:
Johnson & Johnson [JNJ] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.57. With this latest performance, JNJ shares gained by 7.98% in over the last four-week period, additionally sinking by -2.45% over the last 6 months – not to mention a rise of 5.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 61.44, with the RSI for the last a single of trading hit 63.41, and the three-weeks RSI is set at 58.90 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 166.12, while it was recorded at 171.74 for the last single week of trading, and 172.04 for the last 200 days.
Insight into Johnson & Johnson Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +26.11 and a Gross Margin at +68.14. Johnson & Johnson’s Net Margin is presently recorded at +22.27.
Return on Equity for this stock inclined to 30.41, with Return on Assets sitting at 11.70.
Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.
JNJ Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 3.90%.
Johnson & Johnson [JNJ] Insider Position Details
There are presently around $317,172 million, or 71.10% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 242,525,220, which is approximately 1.841% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 205,404,107 shares of the stock with an approximate value of $35.53 billion in JNJ stocks shares; and STATE STREET CORP, currently with $24.4 billion in JNJ stock with ownership of nearly -0.804% of the company’s market capitalization.
Positions in Johnson & Johnson stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,784 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 79,052,701 shares. Additionally, 1,583 investors decreased positions by around 54,185,683 shares, while 375 investors held positions by with 1,700,337,559 shares. The mentioned changes placed institutional holdings at 1,833,575,943 shares, according to the latest SEC report filing. JNJ stock had 118 new institutional investments in for a total of 4,620,676 shares, while 116 institutional investors sold positions of 2,173,574 shares during the same period.